Novel 1,5-naphthyridine PI3K? inhibitors, an evaluation of WO2011075628
Author:
- 23 September 2011
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (11) , 1805-1810
Abstract
A small series of aryl(1-arylamino)ethyl,1,5-naphthyridine derivatives that selectively inhibit PI3Kδ was prepared. The compounds are claimed to be useful in the treatment of cancer, inflammatory and autoimmune diseases. The compounds represent further variations around a structural motif explored in a number of previous applications by the applicant.Keywords
This publication has 7 references indexed in Scilit:
- New phosphatidylinositol 3-kinase inhibitors for cancerExpert Opinion on Investigational Drugs, 2011
- CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viabilityBlood, 2011
- PI3K/p110δ is a novel therapeutic target in multiple myelomaBlood, 2010
- Therapeutic potential of phosphoinositide 3-kinase inhibitorsExpert Opinion on Therapeutic Patents, 2004
- Selective role of PI3Kδ in neutrophil inflammatory responsesBiochemical and Biophysical Research Communications, 2003
- p110δ, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in LeukocytesJournal of Biological Chemistry, 1997
- p110δ, a novel phosphoinositide 3-kinase in leukocytesProceedings of the National Academy of Sciences, 1997